EvolutionaryScale
- Company typePrivate
- Founded2023
- HeadquartersNew York, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
EvolutionaryScale firmographics
Firmographics- Name
- EvolutionaryScale
- Legal name
- EVOLUTIONARYSCALE, PBC
- Website
- https://www.evolutionaryscale.ai
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
EvolutionaryScale industry classification
Industry- Product category
- AI Computational Biology / Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design and Related Services (54151), Other Computer Related Services (541519)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industries
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
Keywords
Where EvolutionaryScale is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
EvolutionaryScale business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Infrastructure, Personnel, Operations, Marketing or Sales
Revenue model
- API Access (Commercial): Paid API access through Forge platform for commercial use of ESM3 models. Tiered pricing based on usage with Industry Model Research Preview available for evaluation.
- Cloud Marketplace Licensing: Pay-as-you-go access through AWS SageMaker for ESMC models (300M, 600M, 6B). Commercial licensing fees for enterprise deployment.
- Non-Commercial API Access: Free API access for non-commercial purposes including academic research, non-profit organizations, research institutes, and educational institutions.
- Open Source Models: Free open-weight models (ESM3-open 1.4B, ESMC 300M) released under non-commercial licenses to build community adoption and scientific goodwill.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Monthly | Non-Commercial Free Tier |
| Usage-based | Pay-as-you-go | Commercial API Access (Forge) |
| Usage-based | Pay-as-you-go | AWS SageMaker Commercial Access |
| Freemium | Monthly | Open Weight Models |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels5 records
EvolutionaryScale product offering
Product offeringCore offering
EvolutionaryScale develops and commercializes frontier AI protein language models for therapeutic and protein engineering applications. Its core products include ESM3, a 98-billion parameter generative model that reasons jointly over protein sequence, structure, and function, and the ESM Cambrian representation learning family. Models are delivered through the Forge API, AWS SageMaker, and NVIDIA BioNemo for commercial pharmaceutical and biotech customers, with free non-commercial access for academic and research institutions.
Product overview
EvolutionaryScale offers a suite of AI models and tools for protein biology research. The core products include ESM3 (a generative language model for creating new proteins), ESM Cambrian (a representation learning model family), ESMC (a protein language model for functional analysis), and ESMFold2 (for structure prediction). These are accessible through the Forge API platform and supported by ESM Atlas (a database of 6.8B+ protein annotations) and the Fold web tool. The company rebranded to Biohub.ai in late 2024/early 2025, unifying EvolutionaryScale and Forge under the Biohub platform.
Differentiator
Problem solved
Functional benefit
Brands
- ESM3: A frontier language model for the life sciences that jointly reasons over protein sequence, structure, and function, enabling scientists to understand, imagine, and create proteins.
- ESM Cambrian
- ESM Atlas
- Forge
- esmGFP
Products and services
- ESM3 Frontier generative protein language model that simultaneously reasons over sequence, structure, and function of proteins, enabling scientists to understand, imagine, and create proteins for therapeutic, research, and clean-energy applications.
- ESM Cambrian Parallel model family to ESM3 focused on protein representation learning rather than generation, available in 300M, 600M, and 6B parameter scales, with state-of-the-art performance across protein understanding tasks.
- ESMC Protein language model that builds representations capturing fundamental mechanisms of protein structure and function from billions of evolutionary sequences, used for functional analysis, structure prediction, and protein design.
- ESMFold2 Model for predicting high-resolution, all-atom 3D structures of biomolecular complexes directly from protein, DNA, and RNA sequences.
- Forge API Platform API platform providing access to ESM3 and ESMC models, with closed-beta and commercial tiers, plus free Industry Model Research Preview for evaluation.
- ESM Atlas Open database providing functional annotations for over 6.8 billion proteins and 1.1 billion paired high-resolution predicted structures, powered by ESM family models.
Quantifiable outcome
- Generated esmGFP, a novel fluorescent protein 58% sequence dissimilar to closest natural protein, representing equivalent of 500+ million years of evolution
- +1 more outcomes
Companies that use EvolutionaryScale
Customer profileSegments3 records
Ideal customer profiles3 records
EvolutionaryScale technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability3 records
Feature6 records
EvolutionaryScale partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core, major and minor.
- Chan Zuckerberg Initiative (CZI) / BiohubcoreCZI acquired EvolutionaryScale as part of restructuring to unify its scientific research entities under Biohub. The acquisition integrates EvolutionaryScale's AI capabilities with CZI's biomedical research mission focused on curing, preventing, and managing diseases through AI-powered scientific research.
- Amazon Web Services (AWS)majorESM3 available on AWS via SageMaker and Bedrock. ESMC models (300M, 600M, 6B) available on AWS Marketplace for commercial deployment. Partnership enables enterprise customers to access models through existing cloud infrastructure.
- NVIDIAmajorESM3 will be available on NVIDIA BioNemo and as an NVIDIA NIM microservice, optimized in collaboration with NVIDIA. Strategic infrastructure partnership for AI model deployment.
- Harvard (Research Reference)minorEvolutionaryScale (which raised $142 million) and Amgen are profiled as key companies in Harvard's overview of AI's role in drug discovery.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
EvolutionaryScale competitors and assessment
Company assessmentDirect peers
- Cradle Bio: Offers a generative AI platform for protein engineering used by biotech and pharma teams. Comparable in providing commercial protein-design APIs and targeting the same therapeutic R&D buyer.
- Profluent Bio: Applies large language models trained on protein sequences to design novel functional proteins, including gene editors. Closely aligned with EvolutionaryScale's protein-LM-first approach and open-model philosophy.
- Absci: Combines generative AI antibody design with a wet-lab validation engine for drug discovery. Closely comparable in applying foundation models to de novo antibody and protein therapeutic design.
- Isomorphic Labs: Alphabet/DeepMind-owned commercial spin-out developing AI for drug discovery, anchored by AlphaFold for protein structure prediction. Most direct competitor in applying large-scale deep learning to protein biology and therapeutic design.
- Generate Biomedicines: Developer of generative biology platforms (Chroma) that design novel protein therapeutics from first principles. Directly comparable in offering generative protein design as a service to pharma partners.
- Iambic Therapeutics: AI-driven drug discovery company combining protein foundation models with physics-based simulation to design small molecules and protein therapeutics. Overlaps in AI-for-protein and AI-for-pharma end markets.
Broad incumbents
- Insilico Medicine: Established AI drug discovery platform spanning target identification, generative chemistry, and clinical development. Broader scope than EvolutionaryScale but directly competes for pharma AI-platform budgets.
- Recursion Pharmaceuticals: Public AI-driven drug discovery company using high-throughput biology and machine learning. Overlaps as a competing AI-for-pharma platform with broader wet-lab and pipeline ambitions.
- Meta AI (Fundamental AI Research / ESM project): Originated the ESM project from which EvolutionaryScale spun out. Continues to release open protein LMs (ESM2, ESMFold) and represents both the academic lineage and a potential open-source competitive ceiling.
Emerging players
- Adaptyv Bio: Cloud protein engineering platform combining AI-driven design with high-throughput wet-lab validation. Smaller and earlier stage, but addresses the same protein-design-from-LM end market with a services overlay.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
EvolutionaryScale social profiles
Digital presenceEvolutionaryScale financial estimates
Financial estimateRevenue estimate
Valuation estimate
EvolutionaryScale leadership team
Management profileNumber of profiles
EvolutionaryScale funding detail
Funding detailFunding overview
Funding rounds1 record
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EvolutionaryScale M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EvolutionaryScale
What does EvolutionaryScale do?
EvolutionaryScale develops and commercializes frontier AI protein language models for therapeutic and protein engineering applications. Its core products include ESM3, a 98-billion parameter generative model that reasons jointly over protein sequence, structure, and function, and the ESM Cambrian representation learning family. Models are delivered through the Forge API, AWS SageMaker, and NVIDIA BioNemo for commercial pharmaceutical and biotech customers, with free non-commercial access for academic and research institutions.
Is EvolutionaryScale a public or private company?
EvolutionaryScale is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was EvolutionaryScale founded?
EvolutionaryScale was founded in 2023. It employs 11 to 50 people.
Where is EvolutionaryScale based?
EvolutionaryScale is headquartered in New York, United States, in the North America region.
How does EvolutionaryScale make money?
Four revenue lines are on record. API Access (Commercial) is the primary driver. The others are cloud Marketplace Licensing, non-Commercial API Access and open Source Models.
Who are EvolutionaryScale's main competitors?
Direct peers on record are Cradle Bio, Profluent Bio, Absci, Isomorphic Labs, Generate Biomedicines and Iambic Therapeutics. Broad incumbents are Insilico Medicine, Recursion Pharmaceuticals and Meta AI (Fundamental AI Research / ESM project). Adaptyv Bio is listed as an emerging player.
Does EvolutionaryScale have an API?
Yes. EvolutionaryScale offers API access to ESM3 and ESMC models through Forge (closed Beta), with models available in three sizes (small, medium, large). ESM3-open (1.4B parameters) with weights and source code available on GitHub under non-commercial license. Models are also available on AWS SageMaker and will be available on NVIDIA BioNemo and AWS Bedrock. Developer documentation is at biohub.ai/api-reference.
What industry is EvolutionaryScale in?
EvolutionaryScale's product category is AI Computational Biology / Drug Discovery. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 8731.